

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	NeuroScientific Biopharmaceuticals Limited
ABN	13 102 832 995

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Brian Leedman
Date of last notice	18 February 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	As director and shareholder of Tashtech Pty Ltd
Date of change	1 March 2021

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p><u>Direct:</u> 2,138,130 Ordinary shares</p> <p>250,000 Class C Performance Shares</p> <p>250,000 Class D Performance Shares</p> <p>250,000 Class E Performance Shares</p> <p>100,000 Listed options (exercisable at \$0.20 on or before 7 March 2021)</p> <p>1,200,000 Unlisted options (exercisable at \$0.30 on or before 17 December 2022)</p> <p><u>Indirect:</u> 91,875 Ordinary shares</p> <p>500,000 Unlisted Options (exercisable at \$0.40 on or before 15 January 2024)</p>
<p>Class</p>	<p>Ordinary Shares, unlisted options and performance</p>
<p>Number acquired</p>	<p>None</p>
<p>Number disposed</p>	<p><u>Direct:</u> 100,000 listed options sold on market</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p><u>Sale:</u> \$370.05 proceeds from sale of 100,000 listed options</p>
<p>No. of securities held after change</p>	<p><u>Direct:</u> 2,138,130 Ordinary shares</p> <p>250,000 Class C Performance Shares</p> <p>250,000 Class D Performance Shares</p> <p>250,000 Class E Performance Shares</p> <p>1,200,000 Unlisted options (exercisable at \$0.30 on or before 17 December 2022)</p> <p><u>Indirect:</u> 91,875 Ordinary shares</p> <p>500,000 Unlisted Options (exercisable at \$0.40 on or before 15 January 2024)</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On market trade, and exercise of options
---	--

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	-
Nature of interest	-
Name of registered holder (if issued securities)	-
Date of change	-
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	-
Interest acquired	-
Interest disposed	-
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	-
Interest after change	-

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	-
If prior written clearance was provided, on what date was this provided?	-

⁺ See chapter 19 for defined terms.